Advertisement

Topics

Companies Related to "Fluphenazine Decanoate for Psoriasis" [Most Relevant Company Matches] RSS

09:05 EST 18th November 2018 | BioPortfolio

Here are the most relevant search results for "Fluphenazine Decanoate for Psoriasis" found in our extensive corporate database of over 50,000 company records.

Showing "Fluphenazine Decanoate Psoriasis" Companies 1–25 of 73

Relevant

National Psoriasis Foundation

The National Psoriasis Foundation is the world's largest nonprofit organization serving people with psoriasis and psoriatic arthritis. Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education. For more information, call the Psoriasis Foundation, headquartered in Portland, Ore., at 800.723.9166, or visit ...


International Federation of Psoriasis Associations

The International Federation of Psoriasis Associations (IFPA) is a non profit umbrella organization made up of psoriasis associations from around the world. Today IFPA has 40 member associations. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the l...

International Psoriasis Council

The International Psoriasis Council (IPC) is a global non-profit organization dedicated to advancing psoriasis research and treatment by providing a forum for education, collaboration, and innovation among physicians, researchers and other professionals interested in psoriasis.


Psoriasis - Matters

www.psoriasis-matters.co.uk is a specialist psoriasis site brought to you by the same team that developed allergymatters.com . www.psoriasis-matters.co.uk will carry the best range of psoriasis UV UVB Light Therapy units and the most suitable creams, ointments and shampoos available in the market. www.psoriasis-matters.co.uk will provide expert reviews and unbiased psoriasis product ratings to un...

Psoriasis Cure Now

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Probably Relevant

Warner Chilcott

Warner Chilcott is a leading specialty pharmaceutical company focused on developing, manufacturing and marketing and selling branded prescription pharmaceutical products in women’s healthcare and dermatology in the United States. We have established strong franchises in these two areas through our precision marketing techniques and specialty sales forces of approximately 400 representatives. We ...

PhotoMedex, Inc.

PhotoMedex is a Global Skin Health Solutions™ company that provides integrated disease management and aesthetic solutions through complementary laser and light-based devices, pharmaceuticals and cosmeceuticals. We are a leader in the development, manufacturing and global marketing of dermatology products and techniques focused on advancing cost-effect...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian S...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver....

Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cance...

AMEVIVE

AMEVIVE is the first biologic approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AMEVIVE is a prescription medication that is injected by your doctor (15 mg IM, into the muscle) once a week for a total of 12 doses.

Johnson and Johnson (France)

Our pharmaceuticals companies offer medicines that treat many of the world's most serious and widespread diseases. These diseases range from cancer, HIV/AIDS and bacterial infections to schizophrenia, epilepsy, rheumatoid arthritis and psoriasis. In 2007, we invested $5.3 billion in the search for new ways to treat these diseases and many others. It’s all part of our commitment to helping you an...

Zelos Therapeutics Inc.

Zelos Therapeutics is an emerging private biopharmaceutical development company that is commercializing breakthrough discoveries in parathyroid hormone (PTH) research. The company is developing medications for the treatment of osteoporosis, psoriasis and for enhancing engraftment following stem cell transplantation. During 2005, Zelos Therapeutics experienced a number of significant milestones. Ke...

Allergymatters

Allergymatters is a unique One Stop Allergy shop dedicated in bringing the finest products available to help manage its customers’ ailments while improving their lifestyle. Allergymatters offers allergy prevention products like the air conditioning systems, portable air conditioners, air purifier, air filter and dehumidifier to maintain the air quality within your house. With the willingness to ...

The Immune Response Corporation

The Immune Response Corporation (OTCBB: IMNR.OB) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimula...

Avontec GmbH

AVONTEC GmbH is a phase II biopharmaceutical company engaged in the development of a novel class of anti-inflammatory drugs that are based on double-stranded DNA oligonucleotides acting as decoys (decoy ODNs) for transcription factors. AVONTECs most advanced clinical development programs focus on the indications asthma (AVT-01) and psoriasis (AVT-02).

Enbrel® (etanercept)

Enbrel® (etanercept) is a TNF inhibitor approved for the following indications: moderately to severely active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and psoriasis.

LEO Pharma A/S

LEO Pharma is a globally, leading pharmaceutical company within Dermatology and Critical Care. We maintain a strong focus on developing, manufacturing and marketing safe and efficacious drugs for treating psoriasis and other skin diseases as well as thromboembolic disorders. LEO Pharma is an independent pharmaceutical company 100 % owned by the LEO Foundation and represented in more than 90 coun...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has ...

NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery ...

TolerRx, Inc.

We are a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat patients with immunological diseases. TolerRx has a development pipeline which includes two humanized antibodies that are in clinical trials for new-onset type 1 diabetes, psoriasis, and cutaneous lupus erythematosus. We also have ongoing research and development programs foc...

Chelsea Therapeutics

We are a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of a variety of human diseases. Our strategy is to develop technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Specifically, Chelsea concentrates its efforts on acquiring and developing technologi...

ARC Pharmaceuticals Inc

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing innovative medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a...

Avexxin

Avexxin is a pharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of psoriasis and other inflammatory disorders. Our discovery and clinical development expertise is...


More From BioPortfolio on "Fluphenazine Decanoate for Psoriasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks